摘要
目的探讨老年不稳定型心绞痛(unstableanginapectoris,UAP)病人早期(24～96小时)应用普伐他汀的疗效及安全性。方法临床确诊为UAP患者72例,随机分为对照组与普伐他汀组各36例,两组均用常规治疗,普伐他汀组加服普伐他汀,于治疗前及治疗后6和12个月时分别测肝功能、肾功能、肌酶谱、总胆固醇(totalcholesterol,TC)、低密度脂蛋白胆固醇(low鄄densitylipoproteincholesterol,LDL鄄C)、一氧化氮(nitricoxide,NO)、C鄄反应蛋白(C鄄reactiveprotein,CRP)、高密度脂蛋白胆固醇(high鄄densitylipoproteincholesterol,HDL鄄C),24小时动态心电图检测心肌缺血总负荷(totalischemicburden,TIB)和心血管缺血相关事件。结果普伐他汀6个月后能有效地降低UAP患者血清TC、LDL鄄C、CRP;升高NO,HLD鄄C;与对照组比较差异有统计学意义(P<0.01)。两组患者每周心绞痛发作次数及TIB均有减少,但普伐他汀组更明显(P<0.05);其缺血相关事件亦有显著性差异(P<0.01)。普伐他汀组中有3例轻度转氨酶升高,2例出现腹胀。结论UAP发病早期应用普伐他汀能安全、有效地降低血脂和CRP,升高NO,显著减少心血管缺血相关事件发生率。
Objectives To explore the effect and safety of pravastatin on patients with unstable angina pectoris(UAP) in early-period (24～96h). Methods 72 patients with UAP were divided into control group(n=36) and pravastatin group (n=36). Myocardial enzyme, liver function, kidney function,total cholesterol(TC),Low-density lipoprotein cholesterol(LDL-C), nitric oxide (NO) ,C-reactive protein(CRP),high-density lipoprotein- cholesterol(HDL-C) were tested and the patients underwent total ischemic burden(TIB), monitoring from 24 hour ambulatory electrocardiogram recording and observation of ischemia related events before, 6 and 12 month after therapy. Results The serum TC,LDL-C,CRP in pravastatin group were obviously decreased than the control group after 6,12 month therapy (P<0.01), the serum NO,HDL-C were markedly increased after 12-month treatment (P<0.05). After treatment, frequency of angina pectoris and TIB of both groups were decreased, but the pravastatin group was further (P<0.05), 3 patients had slightly elevation of ALT and 2 had abdominal distension in pravastatin group. Conclusions Pravastatin is an effective and safety drug for anti-myocardial ischemia and lipid-lowering in early period of UAP. also it can reduce the ischemia related events.
出处
《岭南心血管病杂志》
2005年第2期85-88,共4页
South China Journal of Cardiovascular Diseases
关键词
心绞痛
不稳定型
血脂
普伐他汀
Angina pectoris
Unstable angina pectoris
Serum lipid
Pravastatin
